Allogene Therapeutics (ALLO) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 8.0% versus a gain of 5.9%. Over five years, CAPR leads with a +104.5% price change compared with -91.3% for ALLO. Allogene Therapeutics is the larger company by market cap ($483.7 million vs $460.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | CAPR |
|---|---|---|
| Share price | $1.40 | $7.92 |
| Market cap | $483.72M | $460.50M |
| 1-day change | -2.08% | -2.21% |
| YTD return | +4.38% | -71.93% |
| 1-year return | +5.93% | +8.00% |
| 5-year return | -91.32% | +104.55% |
| EPS (TTM) | $-0.66 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $40.37 |
| 52-week low | $1.04 | $2.96 |
| Distance from 52-week high | -68.61% | -80.38% |
| Analyst consensus | none | buy |
| Avg. price target upside | +542.81% | +240.88% |
| Average volume | 5.65M | 6.85M |
| Shares outstanding | 345.49M | 58.14M |
| Employees | 150 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
ALLO vs CAPR FAQ
Which is bigger, Allogene Therapeutics or Capricor Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $483.72M compared with $460.50M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, ALLO or CAPR?
CAPR returned +8.00% over the past 12 months, compared with +5.93% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Capricor Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Capricor Therapeutics.